View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Bayer AG - December 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Carole Braudeau
  • Carole Braudeau

Credit Morning 04/08/2024

Moody’s cuts Biogroup’s rating to B3/stable from B2/stableS&P upgrads CGG's rating to B-/stable from CCC+/positive>...

Carole Braudeau
  • Carole Braudeau

Morning Crédit 08/04/2024

Moody’s dégrade le rating de Biogroup de B2/stable à B3/stableS&P relève le rating de CGG de CCC+/positive à B-/stable>...

Michael B. Schäfer
  • Michael B. Schäfer

ODDO : Glass half full – Volume recovery started after almost 2 years ...

As Spring approaches, we see industry-wide destocking coming to an end, emerging recovery trends in China gaining momentum and European spot energy cost relief rolling in, all helping to restore plant utilisation and earnings. We add more cyclicality to our preferred names, upgrading BASF to Outperform (Neutral). Momentum being regained in specialties chemicals distribution triggers our upgrade of IMCD to Outperform (Neutral). ‘From record to record’ remains our mantra at FUCHS. ...

Ahmed Ben Salem
  • Ahmed Ben Salem

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 03/19/2024

With momentum around electrification less favourable of late, we have seen a major shift in perception, from doubtless overly rose-tinted optimism to what looks to be similarly excessive pessimism. While we have reduced our BEV assumptions, we nonetheless still anticipate growth in the next few years (including this year), well ahead of that of the automotive market as a whole. In the face of these changes, the players in the value chain (mines, semiconductors, auto) are differently p...

Ahmed Ben Salem
  • Ahmed Ben Salem

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 19/03/2024

Le momentum autour de l’électrification, moins favorable dernièrement, a conduit à un changement profond de perception, passant d’un optimisme sans doute excessif à un pessimisme qui le semble tout autant. En effet, si nous avons revu en baisse nos hypothèses, nous visons néanmoins toujours une croissance dans les années à venir (y compris cette année), bien supérieure à celle du marché automobile dans son ensemble. Face à ces changements, tous les acteurs au sein de la chaîne de vale...

Michael B. Schäfer ... (+2)
  • Michael B. Schäfer
  • Stephan Wulf

Bayer : Low valuation remains justified given ongoing uncertainties

>CMD did not deliver what many investors had hoped for - In recent months, many hopes were pinned on the CMD on 5 March, which was expected to provide more clarity on Bayer's strategic direction. In particular, how to tackle the high level of debt that currently limits financial flexibility, e.g. to invest in the weakening pharma pipeline. At the same time, hopes for a major strategic move, such as the separation of the Consumer Health (CH) division, had already faded...

Carole Braudeau
  • Carole Braudeau
ATO ATOS SE
ORA ORANGE SA ... (+13)

Credit Morning 03/15/2024

Elis: new bond issue maturing in 2030Ageas: BNP is said to weigh purchase of Fosun’s Ageas stakeVodafone reaches an agreement to sell Vodafone Italy to Swisscom for € 2bn in cashTHOM: resilient Q1 results without any major surprise after the figures released as part of the issuance.>...

Carole Braudeau
  • Carole Braudeau
ATO ATOS SE
ORA ORANGE SA ... (+13)

Morning Crédit 15/03/2024

Elis : émission d’une nouvelle obligation à échéance 2030Ageas : BNP considérerait la reprise de la participation de 10% de Fosun au capital d’AgeasVodafone annonce un accord de cession de Vodafone Italie à Swisscom pour 8 mds EUR en cashTHOM : des résultats T1 résilients mais sans surprise après les chiffres communiqués dans le cadre de l’émission>...

Carole Braudeau
  • Carole Braudeau

Credit Morning 03/13/2024

Vallourec: ArcelorMittal becomes reference shareholderZalando: liquidity further strengthened at end 2023. Outlook and mid-term targets in line.>...

Carole Braudeau
  • Carole Braudeau

Morning Crédit 13/03/2024

Vallourec : ArcelorMittal devient l’actionnaire de référenceZalando : une situation de cash encore renforcée à l’issue de l’exercice 2023. Perspectives conformes au consensus.>...

Carole Braudeau
  • Carole Braudeau

Credit Morning 03/12/2024

S&P downgrades ELO to BB+/stableThyssenkrupp Elevator successfully places € 3.7bn term loan>...

Carole Braudeau
  • Carole Braudeau

Morning Crédit 12/03/2024

S&P a dégradé le rating d’ELO à BB+/stableThyssenkrupp Elevator place avec succès 3.7 mds EUR de term loan>...

Research Department
  • Research Department

INFORME DIARIO 12 MARZO (ANÁLISIS BANCO SABADELL)

COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: GRIFOLS, OHLA, TELEFONICA. EUROPA: BAYER, SIEMENS. El Ibex salva la jornada A la espera del dato de inflación de hoy en EE.UU., que pueda dar pistas sobre el comienzo de las bajadas de tipos por parte de la Fed, la jornada fue de recogidas de beneficios para la mayoría de índices europeos, a excepción del Ibex (ha subido en 6 de las últimas 7 sesiones). Así, en el STOXX 600, la mayoría de los sectores cerraron con caídas, lideradas por Tecnología y ...

Salome Charamalet ... (+2)
  • Salome Charamalet
  • Stefano Toffano

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 03/07/2024

We are initiating coverage of Lonza with a target price of CHF 535 and an Outperform rating. As one of the world's leading contract development and manufacturing organisations (CDMO), Lonza is predestined to benefit from the sustainable drivers of this industry. The group's global presence and strong market positions in the growth areas of biologics and cell and gene therapy (CGT) will fuel double-digit sales growth and >30% EBITDA margins in the medium term. Despite significant growt...

Salome Charamalet ... (+2)
  • Salome Charamalet
  • Stefano Toffano

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 07/03/2024

We are initiating coverage of Lonza with a target price of CHF 535 and an Outperform rating. As one of the world's leading contract development and manufacturing organisations (CDMO), Lonza is predestined to benefit from the sustainable drivers of this industry. The group's global presence and strong market positions in the growth areas of biologics and cell and gene therapy (CGT) will fuel double-digit sales growth and >30% EBITDA margins in the medium term. Despite significant growt...

Carole Braudeau
  • Carole Braudeau

Credit Morning 03/06/2024

Cellnex: new guidance, agreement to sell Irish operations and IG rating at S&PGrifols A: Moody’s places Grifols’ B2 corporate rating on review for downgrade>...

Carole Braudeau
  • Carole Braudeau

Morning Crédit 06/03/2024

Cellnex : nouvelle guidance, accord de vente de Cellnex Irlande et obtention d’un rating IG chez S&PGrifols A : Moody’s place le rating corporate B2 de Grifols sous surveillance en vue d’une dégradation>...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch